logo
Citing worsening macro conditions, Frasers Property renews bid to take Frasers Hospitality Trust private

Citing worsening macro conditions, Frasers Property renews bid to take Frasers Hospitality Trust private

Business Times14-05-2025

[SINGAPORE] Frasers Property is proposing to privatise Frasers Hospitality Trust (FHT) at S$0.71 per stapled security, due to FHT's inability to improve the distribution and growth of FHT in the face of macroeconomic headwinds.
This is the second time in three years that Frasers Property has attempted to privatise the stapled group. It tried to do so in September 2022 for S$0.70 per stapled security, though the privatisation attempt failed then after being voted down by shareholders.
In a statement on Wednesday (May 14), FHT's manager said the decision followed a strategic review of FHT amid a worsening macroeconomic environment. It said a weaker foreign exchange rate against the Singapore dollar and a higher interest rate environment, among other factors, have made it more difficult for the managers of FHT to grow its distribution and net asset value (NAV).
The current offer price of S$0.71 apiece implies a 1.11 times, or 11.1 per cent, premium over its NAV, and exceeds the implied average premium over NAV of former Singapore real estate investment trust (Reit) privatisations since 2020 of 1.04 times.
As at the time of the announcement, FHT has issued about 1.9 billion stapled securities.
'We have put forward an offer for FHT which safeguards the interests of Frasers Property's shareholders. The arm's length offer was arrived at after taking into consideration the financial and business effects of the privatisation to Frasers Property, both over the short and long term, in addition to a number of FHT financial reference points,' said Loo Choo Leong, group chief financial officer of Frasers Property.
A NEWSLETTER FOR YOU
Tuesday, 12 pm Property Insights
Get an exclusive analysis of real estate and property news in Singapore and beyond.
Sign Up
Sign Up
During a briefing to the media on Wednesday afternoon, Eric Gan, chief executive of FHT's manager, said the macroeconomic environment has gone 'further south' since the last attempt to privatise FHT in 2022.
'Foreign exchange has continued to weaken further. Interest rate has risen, further impacting us,' he said.
The Covid-19 pandemic has also had a 'significant, lasting impact' on FHT's valuation. While FHT was trading at 0.95 times its NAV prior to the pandemic, the trust's valuation has become 'worse' after the pandemic, trading at 0.73 times its NAV, said Gan.
FHT has faced challenges attracting capital flow due to its scale and size. As a small Reit and small float, it is unable to attract institutional investors to grow meaningfully. It also does not have as much debt headroom as its peers to engage in acquisitions.
Privatisation route offers 'certainty'
During FHT's strategic review last month, the board considered several options to unlock the trust's potential value, said Gan.
These include keeping FHT listed, but potentially divesting selected assets or rebalancing its portfolio. The manager also considered selling the entire platform to a third party and distributing the net proceeds to securityholders.
However, the board eventually agreed that privatisation was the best way forward, as it would allow stapled securityholders to immediately realise their investment at a premium to NAV. It would also offer certainty as it will be executed by the sponsor, which has obtained the financial resources to conduct the privatisation exercises.
Gan was optimistic that the manager would be successful in its bid to privatise FHT this time around.
In 2022, Frasers Property attempted to privatise the stapled group for S$0.70 per stapled security. However, the resolution narrowly missed the minimum approval level of votes representing 75 per cent of units required for it to be passed at the September 2022 scheme meeting. It attained favourable votes representing 74.88 per cent of units from around 70.91 per cent of stapled securityholders.
Gan was of the view that the latest offer price of S$0.71 is 'a lot higher' than S$0.70 when compared in terms of the premium it offers on the NAV. While the previous offer of S$0.70 was at a 7 per cent premium to NAV, the latest offer is higher at 11 per cent.
Said Gan: 'Don't just look at one cent, but look at the percentage. I think that speaks volumes, because 11.1 per cent is a lot higher than any of the other metrics.'
On May 6, FHT reported a 6 per cent drop in its distribution per stapled security to S$0.010257 for its first half year ended Mar 31, from S$0.01091 in the corresponding year-ago period, in light of lower net property income (NPI) and higher finance costs.
NPI for the period fell 2.5 per cent on the year to S$43.5 million from S$44.7 million, while revenue rose 0.9 per cent to S$63.8 million from S$63.3 million in H1 FY2024, due to increased contributions from Koto no Hako – the retail component of ANA Crowne Plaza Kobe – and higher other income.
The scheme is expected to be effective by end-August 2025, subject to the approval of the scheme stapled securityholders and various other conditions being fulfilled. The scheme meeting for stapled securityholders is expected to be in late July.
Stapled securities of FHT were trading flat at S$0.665 as at 2 pm on Wednesday, following the lifting of a trading halt.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Singapore Paincare up 12.1% as Sias urges shareholders to await IFA report
Singapore Paincare up 12.1% as Sias urges shareholders to await IFA report

Business Times

time8 hours ago

  • Business Times

Singapore Paincare up 12.1% as Sias urges shareholders to await IFA report

[SINGAPORE] Shares of Singapore Paincare rose on Thursday (Jun 5), a day after the Securities Investors Association (Singapore), or Sias, said the medical services company could be worth more than double its privatisation offer price. As at 4.19 pm, the counter was trading at S$0.176, 12.1 per cent or S$0.019 above the previous closing price of S$0.157 on Wednesday, with 15.2 million shares transacted. This was its highest price in the year to date. It closed on Thursday 8.3 per cent or S$0.013 higher at S$0.17, with 17.3 million shares having changed hands. On Wednesday, Sias urged minority shareholders of Singapore Paincare to hold off selling their shares amid an acquisition bid from Advance Bridge Healthcare, a management consultancy for healthcare services. Sias noted that the company could be worth around S$0.36 to S$0.37 a share, more than double the S$0.16 a share privatisation offer price. It recommended that shareholders wait and refrain from taking action until the report by the independent financial adviser (IFA) is released. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up 'If the shares are sold on the open market, shareholders who sold will not have recourse if there is subsequent upward revision in the offer price,' Sias warned. There have been past instances when shareholders sought slight gains and sold their shares on the open market before the IFA issued its report, it noted. Moreover, the S$0.37 per share offer price is at a 'slight discount' to the company's audited net asset value (NAV) per share of S$0.166 as at Jun 30, 2024, it said. The association highlighted that Singapore Paincare made its July 2020 trading debut during Covid-19 with an initial public offering (IPO) price of S$0.22 per share, when valuations were depressed and when the Straits Times Index (STI) was trading at around 2,500 points. The IPO price of S$0.22 was a 123 per cent premium to the group's unaudited NAV per share of about S$0.0986 on Dec 31, 2019, based on the post-placement share capital and after adjusting for net proceeds due to the company from the placement. 'It now wishes to delist at S$0.16 per share when the STI is trading at around 3,900 points... If the same IPO premium were to be applied now, the privatisation price should be around S$0.36 to S$0.37,' Sias said. 'For a delisting to take place, the IFA has to conclude that the offer is both fair and reasonable... it would therefore be advisable to wait for the IFA's opinion.'

Singapore Paincare up 12.1% on Sias valuation
Singapore Paincare up 12.1% on Sias valuation

Business Times

time9 hours ago

  • Business Times

Singapore Paincare up 12.1% on Sias valuation

[SINGAPORE] Shares of Singapore Paincare rose on Thursday (Jun 5), a day after the Securities Investors Association (Singapore), or Sias, valued the medical services company at more than double its privatisation offer price. As at 4.19 pm, the counter was trading at S$0.176, 12.1 per cent or S$0.019 above the previous closing price of S$0.157 on Wednesday, with 15.2 million shares transacted. This was its highest price in the year to date. It closed on Thursday 8.3 per cent or S$0.013 higher at S$0.17, with 17.3 million shares having changed hands. On Wednesday, Sias urged minority shareholders of Singapore Paincare to hold off selling their shares amid an acquisition bid from Advance Bridge Healthcare, a management consultancy for healthcare services. Sias noted that the company could be worth S$0.37 a share, more than double the S$0.16 a share privatisation offer price. It recommended that shareholders wait and refrain from taking action until the report by the independent financial adviser (IFA) is released. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up 'If the shares are sold on the open market, shareholders who sold will not have recourse if there is subsequent upward revision in the offer price,' Sias warned. There have been past instances when shareholders sought slight gains and sold their shares on the open market before the IFA issued its report, it noted. Moreover, the S$0.37 per share offer price is at a 'slight discount' to the company's audited net asset value (NAV) per share of S$0.166 as at Jun 30, 2024, it said. The association highlighted that Singapore Paincare made its July 2020 trading debut during Covid-19 with an initial public offering (IPO) price of S$0.22 per share, when valuations were depressed and when the Straits Times Index (STI) was trading at around 2,500 points. The IPO price of S$0.22 was a 123 per cent premium to the group's unaudited NAV per share of about S$0.0986 on Dec 31, 2019, based on the post-placement share capital and after adjusting for net proceeds due to the company from the placement. 'It now wishes to delist at S$0.16 per share when the STI is trading at around 3,900 points... If the same IPO premium were to be applied now, the privatisation price should be around S$0.36 to S$0.37,' Sias said. 'For a delisting to take place, the IFA has to conclude that the offer is both fair and reasonable... it would therefore be advisable to wait for the IFA's opinion.'

Nintendo Switch 2 launches globally with shortages expected amid pent-up demand
Nintendo Switch 2 launches globally with shortages expected amid pent-up demand

New Paper

time14 hours ago

  • New Paper

Nintendo Switch 2 launches globally with shortages expected amid pent-up demand

Nintendo's Switch 2 launched on June 5 and is widely expected to be in short supply globally amid pent-up demand for the more powerful next-generation gaming device. "The level of demand seems to be sky-high," said Mr Serkan Toto, founder of the Kantan Games consultancy. The Switch launched in 2017 and followed the underperforming Wii U. The home-portable device became a juggernaut with games including two The Legend Of Zelda titles and Covid-19 pandemic breakout hit Animal Crossing: New Horizons. The Switch 2 bears many similarities with its predecessor but offers a larger screen and improved graphics and debuts with titles including Mario Kart World. "The much larger audience of Switch users should translate to stronger adoption in the opening part of its life-cycle," said Mr Piers Harding-Rolls, an analyst at Ampere Analysis. "Nintendo is better prepared this time around" to deal with the high demand, he said. The launch of the US$499.99 (S$643) Switch 2 is a test of Nintendo's supply chain management during United States President Donald Trump's trade war. Nintendo in May forecast sales of 15 million Switch 2 units during the current financial year. President Shuntaro Furukawa said Nintendo will strengthen production capacity to respond to strong demand and focus on sales promotion in an effort to exceed the forecast. The company, which is known for conservative forecasts, also expects to sell 4.5 million Switch units. A staff member at an electronics store in Tokyo holds a megaphone on June 5, the day Nintendo starts selling the Nintendo Switch 2 game console globally. PHOTO: REUTERS Nintendo said it received 2.2 million applications for its Switch 2 sales lottery on its official site My Nintendo Store in Japan. Pre-orders at Target sold out in less than two hours. "You are looking at weeks or months until you can walk into a store and buy a Switch 2," said Mr Toto of Kantan Games. Investor expectations for the new device are similarly lofty. Nintendo's shares are trading near highs and have gained almost 30 per cent in 2025. Concerns include whether momentum for the Switch 2 will be sustained after hardcore gamers have upgraded. "The volume of first-party games on offer at launch isn't as strong as it could be, so some more casual users may wait and see how the games available build over the next one to two years before making the leap," said Ampere's Mr Harding-Rolls. Ampere forecasts Switch 2 sales to exceed 100 million units in 2030. Nintendo has sold 152 million Switch units in total.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store